A pathological hallmark of Parkinson’s and other neurodegenerative disorders, alpha-synuclein accumulation into Lewy bodies is thought to play a major role in the onset and/or progression of disease. Clinical trials are ongoing for several potential treatments targeting extracellular alpha-synuclein. MJFF will support projects aimed at altering intracellular alpha-synuclein in order to broaden the scope of therapeutic approaches.

Deadlines

Pre-Proposals Due:

Full Proposal Invitations:

Full Proposals Due (by invite only):

Anticipated Award Announcement:

Anticipated Funding:

Fall 2018

May 31, 2018 – 5 p.m. US ET

July 2018

August 20, 2018 – 5 p.m. US ET

October 2018

November 2018

FUNDING OPPORTUNITIES INFORMATIONAL WEBINAR

May 10, 2018

12 p.m. - 1 p.m. US ET

This webinar provides an overview of MJFF's funding strategy, MJFF's funding opportunities and how to apply for funding and the review process.